CDK4 and neoplasm: The triple combination-treated group contained significantly fewer metastasis (defined, approximately, as tumor area > 2500 μm2) compared to the combined fulvestrant and CDK4/6i-treated group at 6 weeks of treatment in both MPF-R (p = 0.050, Fig. 6E) and TPF-R (p = 0.042, Fig. 6F) models.